ArticleGene therapy2004
An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Engineering approaches for RNA-based and cell-based osteoarthritis therapies.Nature reviews. Rheumatology · 2024Review
- Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries.Bioactive materials · 2022Review
- A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues.Tissue engineering. Part A · 2019Article
- Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model.Human gene therapy. Clinical development · 2018Article
- Genome Engineering for Personalized Arthritis Therapeutics.Trends in molecular medicine · 2017Review
- Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs.Stem cell reports · 2017Article
- Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.Scientific reports · 2016Article
- Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines.Cancer gene therapy · 2015Article
- Article
- IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.Journal of molecular medicine (Berlin, Germany) · 2012Article
- Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice.PloS one · 2012Article
- Early gestational gene transfer of IL-10 by systemic administration of lentiviral vector can prevent arthritis in a murine model.Gene therapy · 2011Article
- PTHrP overexpression partially inhibits a mechanical strain-induced arthritic phenotype in chondrocytes.Osteoarthritis and cartilage · 2011Article
- Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.BMC biotechnology · 2010Article
- Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Orthopedic gene therapy in 2008.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Gene therapy of the rheumatic diseases: 1998 to 2008.Arthritis research & therapy · 2009Review
- Gene therapy for arthritis.Modern rheumatology · 2008Review
- Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis.Gene therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To achieve a disease-regulated transgene expression for physiologically responsive gene therapy of arthritis, a hybrid promoter was constructed. The human IL-1 beta enhancer region (-3690 to -2720) upstream of the human IL-6 promoter region (-163 to +12) was essential in mounting a robust response in HIG-82 synovial fibroblasts and in RAW 264,7 macrophages. A replication-deficient adenovirus was engineered with luciferase (Luc) controlled by the IL-1/IL-6 promoter (Ad5.IL-1/IL-6-Luc). LPS caused a 23- and 4.6-fold induction of Luc. activity in RAW cells infected with Ad5.IL-1/IL-6-Luc or the conventional Ad5.CMV-Luc construct, respectively. Next, adenoviruses (10(6) ffu) were injected into the knees of C57Bl/6 mice. An intra-articular injection of zymosan, 3 days after Ad5.IL-1/IL-6-Luc, increased Luc. activity by 39-fold but had no effect in the Ad5.CMV-Luc joints. The constitutive CMV promoter was rapidly silenced and could not be reactivated in vivo. In contrast, the IL-1/IL-6 promoter could be reactivated by Streptococcal cell wall (SCW)-induced arthritis up to 21 days after infection. Next the IL-1/IL-6 promoter was compared to the C3-Tat/HIV-LTR two-component system in wild-type, IL-6(-/-) and IL-1(-/-) gene knockout mice. Both systems responded well to LPS-, zymosan- and SCW-induced arthritis. However, the basal activity of the IL-1/IL-6 promoter was lower and IL-6 independent. This study showed that the IL-1/IL-6 promoter is feasible to achieve disease-regulated transgene expression for treatment of arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.